Edit

CARSGEN

http://www.carsgen.com/
Last activity: 29.04.2024
Categories: CarCartDevelopmentManufacturingPlatformProduct
CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.
Website visits
14.5K /mo.
Mentions
38
Employees: 201-500
Total raised: $30M
Founded date: 2014
Email

Investors 1

Funding Rounds 1

DateSeriesAmountInvestors
25.01.2016Series B$30M-

Mentions in press and media 38

DateTitleDescriptionSource
29.04.2024CARsgen Submitted Responses to FDA ObservationsSHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...en.prnasia...
27.03.2024CARsgen Announced 2023 Annual ResultsSHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stoc...en.prnasia...
01.03.2024NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevor...SHANGHAI, March 1, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...en.prnasia...
19.01.2024CARsgen's Presents Updated Research Results on CT041 at 2024...SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...en.prnasia...
15.01.2024CARsgen's CT011 achieves IND clearance from the NMPA for the...SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...en.prnasia...
12.12.2023CARsgen Presents Updated Research Results on Zevor-cel at 20...SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...en.prnasia...
04.12.2023CARsgen's CT071 Received IND Clearance from the FDA for Trea...SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), ...en.prnasia...
20.11.2023CARsgen Announces Formation of its Clinical Advisory BoardSHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...en.prnasia...
12.10.2023CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellula...SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK),...en.prnasia...
21.09.2023Two Cases of Pancreatic Cancer Treatment with CARsgen's CT04...SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK)...en.prnasia...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In